Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Establishes distribution center in top hub for international shipping
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Dr. Mandaviya urged the stakeholders to capitalize on the current opportunities
Indian government seeks to promote collaboration with stakeholders and harness potential for achieving growth and development of sector
8th Edition of the event to promote India as a manufacturing hub of quality medical products in the Pharmaceutical and Medical Devices Sector
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Single dose of Ferric Carboxymaltose (FCM) up to 750 mg of iron can be infused in 15 minutes
Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India
Subscribe To Our Newsletter & Stay Updated
